MGLL and Alzheimer disease: Finally, we blocked Mgll activity and expression using a Mgll inhibitor (JZL 184, 1 μM) (Figure 7F, two-way ANOVA: Genotype x treatment F (1, 8) = 5.896, P = 0.0721; Genotype F (1, 8) = 10.88, P = 0.03; Treatment F (1, 8) = 13.69, P = 0.0208, n = 12, Tukey's post-hoc test, * P < 0.05) and Mgll shRNAs (Figure 7I, two-way ANOVA: Genotype x treatment F (1, 8) = 1.791, P = 0.2176; Genotype F (1, 8) = 12.64, P = 0.0074; Treatment F (1, 8) = 12.11, P = 0.0083, n = 12, Tukey's post-hoc test, * P < 0.05) respectively, in P2 3xTg-AD NPCs and observed a similar rescuing effect.